Sugi Predict

Sugi Predict / Compounds / SCHEMBL3521714

SCHEMBL3521714

SCHEMBL3521714

Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(CC(=O)N3CCN(C(=O)OC(C)(C)C)CC3)noc2c1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 15/20 0.59
▸ MAPK13 O15264 2/20 0.59
▸ RIPK2 O43353 1/20 0.54
▸ HDAC4 P56524 2/20 0.47
▸ KIT P10721 7/20 0.45
▸ KDR P35968 6/20 0.45
▸ LCK P06239 4/20 0.45
▸ MAPK9 P45984 4/20 0.45
▸ SGK1 O00141 1/20 0.45
▸ RAF1 P04049 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524761 0.89 MAPK13 (0.71) MAPK14MAPK13KITKDRLCK
SCHEMBL3528047 0.88 MAPK13 (0.72) MAPK14MAPK13RIPK2KITKDR
SCHEMBL3521553 0.88 MAPK13 (0.75) MAPK14MAPK13RIPK2HDAC4KIT
SCHEMBL3527377 0.87 MAPK14 (0.65) MAPK14MAPK13RIPK2KITKDR
SCHEMBL3527991 0.86 MAPK14 (0.68) MAPK14MAPK13KITKDRLCK
SCHEMBL3526077 0.83 MAPK14 (0.74) MAPK14MAPK13KITKDRLCK
SCHEMBL13546255 0.83 MAPK14 (0.70) MAPK14MAPK13KITKDRLCK
SCHEMBL3526283 0.83 MAPK14 (0.72) MAPK14MAPK13RIPK2KITKDR
SCHEMBL6170038 0.81 MAPK13 (0.54) MAPK14MAPK13RIPK2HDAC4KIT
SCHEMBL3525332 0.81 MAPK14 (0.70) MAPK14MAPK13KITKDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642276-B2 Fused heteroaryl derivatives for use as P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-01-05 — — US disclosed
US-7642276-B2 Fused heteroaryl derivatives for use as P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-01-05 — — US disclosed
US-7642276-B2 Fused heteroaryl derivatives for use as P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-01-05 — — US disclosed
EP-1531812-B1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS SMITHKLINE BEECHAM CORP (US) 2007-06-27 — — EP disclosed
US-20060122221-A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis SMITHKLINE BEECHAM CORPORATION 2006-06-08 — — US disclosed
EP-1531812-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2005-05-25 — — EP disclosed
WO-2004010995-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122221-A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis MAPK7, CNKSR1, MAPK1 MAPK14 11/4885MAPK13 19/4885RIPK2 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.